<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Zhang L</submitter><funding>National Natural Science Foundation of China</funding><funding>Scientific Research Special Funds of Provincial Colleges and Universities</funding><funding>Foundation for Key Teacher by Henan University of Technology</funding><funding>Program for Science and Technology Innovation Talents in Universities of Henan Province</funding><pagination>391-406</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6351124</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>15(3)</volume><pubmed_abstract>Currently, particular focus is placed on the implication of autophagy in a variety of human diseases, including cancer. Discovery of small-molecule modulators of autophagy as well as their potential use as anti-cancer therapeutic agents would be of great significance. To this end, a series of curcumin analogs previously synthesized in our laboratory were screened. Among these compounds, (3E,5E)-3-(3,4-dimethoxybenzylidene)-5-[(1H-indol-3-yl)methylene]-1-methylpiperidin-4-one (CA-5f) was identified as a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. We found that CA-5f neither impaired the hydrolytic function nor the quantity of lysosomes. Use of an isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomic screen in combi</pubmed_abstract><journal>Autophagy</journal><pubmed_title>Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.</pubmed_title><pmcid>PMC6351124</pmcid><funding_grant_id>no. 001170</funding_grant_id><funding_grant_id>no. 15HASTIT031</funding_grant_id><funding_grant_id>no. 31471296</funding_grant_id><funding_grant_id>no. 2015RCJH04</funding_grant_id><pubmed_authors>Jing H</pubmed_authors><pubmed_authors>Qiang P</pubmed_authors><pubmed_authors>Cui L</pubmed_authors><pubmed_authors>Qu J</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Yu J</pubmed_authors><pubmed_authors>Yao X</pubmed_authors><pubmed_authors>Liu Y</pubmed_authors><pubmed_authors>Chen Z</pubmed_authors><pubmed_authors>Zhao Q</pubmed_authors><pubmed_authors>Miao Y</pubmed_authors><pubmed_authors>Liu B</pubmed_authors><pubmed_authors>Sun G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Identification of compound CA-5f as a novel late-stage autophagy inhibitor with potent anti-tumor effect against non-small cell lung cancer.</name><description>Currently, particular focus is placed on the implication of autophagy in a variety of human diseases, including cancer. Discovery of small-molecule modulators of autophagy as well as their potential use as anti-cancer therapeutic agents would be of great significance. To this end, a series of curcumin analogs previously synthesized in our laboratory were screened. Among these compounds, (3E,5E)-3-(3,4-dimethoxybenzylidene)-5-[(1H-indol-3-yl)methylene]-1-methylpiperidin-4-one (CA-5f) was identified as a potent late-stage macroautophagy/autophagy inhibitor via inhibiting autophagosome-lysosome fusion. We found that CA-5f neither impaired the hydrolytic function nor the quantity of lysosomes. Use of an isobaric tag for relative and absolute quantitation (iTRAQ)-based proteomic screen in combi</description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Mar</publication><modification>2026-04-07T14:35:33.257Z</modification><creation>2019-09-12T07:00:57Z</creation></dates><accession>S-EPMC6351124</accession><cross_references><pubmed>30145925</pubmed><doi>10.1080/15548627.2018.1511503</doi></cross_references></HashMap>